A gene signature predicts chemotherapy response in pancreatic cancer models, according to data Dr. Sergio Attanasio presented at #AACR26. A new oxidative phosphorylation inhibitor, IM156, is undergoing further study in a Phase 1b clinical trial. Read more: https://t.co/AxxjtWD5LR #EndCancer